With regard to the power calculations please note the following. The population covered by the present study consists of all subjects potentially affected with myopic CNV. It is a population of modalities, and therefore, is unlimited. The sample was selected according to inclusion and exclusion criteria, mentioned in the “Methods.” From a statistical point of view, it is a simple, random, no orderly sample without replacement: it is a nonprobabilistic sample with reasoned choice, which does not allow the application of the Horvitz-Thompson estimator to estimate variance, and then errors and best sample size. We elected to enroll every eligible patient who sought treatment from February 2008 through December 2008; therefore, the sample size was left to chance. The 1-tailed paired t test we used to compare the best-corrected visual acuity (BCVA) results applies with the compound hypothesis; therefore, the test power 1 - beta cannot be determined by the Neyman-Pearson lemma. The Neyman-Pearson test, indeed, applies to the case of a simple null hypothesis against a simple alternative hypothesis; on the contrary, the 1- beta varies with an alternate hypothesis. With a sample size of 16 patients in each arm, we found a standard deviation equal to 8.413 for BCVA in the bevacizumab group. We can assume a prudential alternate hypothesis of BCVA improvement equal to 7 letters; given an alfa error of 5%, we obtain a power of 0.942, and therefore a beta error of 5.8%. As for the proportional confidence interval of a complication rate, it is absolutely arbitrary to evaluate as 25% because we could not examine the problem, not being detected over all of the 32 patients. This means that the probability of complications is less than 3%, corresponding to a maximum proportional confidence interval equal to 11.7%, with an error of 5%.